GW researchers successfully used CRISPR/Cas9 to limit the impact of schistosomiasis and liver fluke infection, affecting more than a quarter of a billion people in Southeast Asia, sub-Saharan Africa, and Latin America
For the first time, researchers at the George Washington University (GW), together with colleagues at institutes in Thailand, Australia, the U.K. and the Netherlands, and more, have successfully used the gene-editing tool CRISPR/Cas9 to limit the impact of parasitic worms responsible for schistosomiasis and for liver fluke infection, which can cause a diverse spectrum of human disease including bile duct cancer. Their findings are found in two papers published today in the journal eLife.
“The genes we ‘knocked out’ using CRISPR/Cas9 resulted in markedly diminished symptoms of infection in our animal models,” said Paul Brindley, PhD, professor of microbiology, immunology, and tropical medicine at the GW School of Medicine and Health Sciences, and lead author. “Our research also showed that this revolutionary new biomedical procedure — CRISPR/Cas9 — can be adapted to study helminth parasites, which are a major public health problem in tropical climates.”
CRISPR/Cas9 is a new technology that allows researchers to precisely target and deactivate the genetic information needed to produce a particular protein. While the tool has been used in other species before, it was unknown if it could be applied to Schistosoma mansoni and Opisthorchis viverrini, the parasites responsible for schistosomiasis and liver fluke infection.
Schistosomiasis can cause serious health problems, including damage to the liver and kidneys, infertility and bladder cancer. The freshwater worms S. mansoni enter the human body by burrowing into the skin; once in the bloodstream, they move to various organs where they rapidly start to reproduce. Their eggs release several molecules, including a protein known as omega-1 ribonuclease, which can damage the surrounding tissues. Brindley and his research team “knocked out” this protein using CRISPR/Cas9 and found that it greatly reduced the impact of the disease.
Liver fluke infection can cause a type of liver cancer called bile duct cancer, triggered by the presence of the worm O. viverrini. This parasite is transmitted through traditional Southeast Asian cuisines using uncooked or undercooked fish. Once inside the body, the parasite settles in the human liver and secretes a protein known as granulin that may encourage liver cells to multiply, raising the risk for cancer. Brindley and his research team used CRISPR/Cas9 to deactivate the gene that codes for granulin and create parasites that can only produce very little of the protein, leading to markedly reduced symptoms of liver fluke infection.
“These neglected tropical diseases affect more than a quarter of a billion people primarily living in Southeast Asia, sub-Saharan Africa, and Latin America,” said Brindley. “CRISPR/Cas9 is a tool that may be used to limit the impact of these infections. As we work to better understand how these parasites invade and damage our bodies through this new technology, we will find new ideas for treatment and disease control.”
The Latest on: CRISPR/Cas9
via Google News
The Latest on: CRISPR/Cas9
- Study identifies pitfall for correcting mutations in human embryos with CRISPRon October 29, 2020 at 8:28 am
The most detailed analysis to date of CRISPR genome editing in human embryos finds a significant risk of chromosomal abnormalities when using the technique at earliest stage of human development.
- CRISPR-Cas9 may help battle sea lice in Atlantic salmonon October 27, 2020 at 5:00 pm
Study to draw on natural abilities of Pacific salmon to fight sea lice. Sea lice are naturally occurring parasites that attach to and feed on salmon. Infestation of salmon farms can be common and ...
- CRISPR CAS9 TECHNOLOGYon October 22, 2020 at 11:13 pm
New York, May 30 (IANS) The CRISPR-Cas9 gene-editing technology can introduce hundreds of unintended mutations into the genome, warns a new study. The paper-strip uses cutting-edge CRISPR gene-editing ...
- CRISPR-Cas9 Gene Therapy Reduces Severity of Angelman Syndrome in Miceon October 22, 2020 at 5:00 am
A new study lays important groundwork for a long-lasting treatment, or even cure, for Angelman syndrome—as well as a therapeutic path forward for other single-gene disorders. Babies born with a faulty ...
- ERS Genomics Announces Agreement with FASMAC to Commercialize CRISPR/Cas9 Research Reagents in Japanon October 13, 2020 at 9:52 pm
ERS Genomics Limited ("ERS"), which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed ...
- Emmanuelle Charpentier Had To Leave France To Be Allowed To Do The Science For Her CRISPR-Cas9 Nobelon October 12, 2020 at 12:12 pm
With CRISPR-Cas9 finally getting its Nobel Prize pundits talk about who was excluded, like Feng Zhang and his research group at the Broad Institute, but only a few talk about entire countries left out ...
- The Nobel Prize For CRISPR-Cas9: Here's Who Got Left Outon October 8, 2020 at 1:15 pm
This year’s Nobel prize in chemistry was awarded for a genuine revolution in modern science. The Crispr-Cas9 gene-editing tool allows scientists to precisely alter DNA by cutting and pasting sections ...
- Why 2020 Chemistry Nobel went to CRISPR-Cas9 tool that can ‘rewrite code of life’on October 8, 2020 at 2:55 am
Doudna for their work on the development of CRISPR-Cas9, a cutting edge, novel method for genome editing. This is the first time a Nobel has been awarded jointly to two women, after decades of ...
- Nobel Prize in Chemistry 2020: CRISPR/Cas9 method for genome editingon October 7, 2020 at 6:09 am
Doudna for the development of the CRISPR/Cas9 method for genome editing. The Royal Swedish Academy of Sciences has decided to award the Nobel Prize in Chemistry 2020 to Emmanuelle Charpentier ...
- CRISPR-Cas9 Tech Pioneer UC Berkeley Biochemist Jennifer Doudna Awarded Nobel Prize In Chemistry; ‘I’m In Shock’on October 7, 2020 at 5:27 am
Working on opposite sides of the Atlantic, Charpentier and Doudna came up with a method known as CRISPR-cas9 that can be used to change the DNA of animals, plants and microorganisms with extremely ...
via Bing News